Medicine guide
Kyinsu
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Insulin icodec;semaglutide
- Made by
- Novo Nordisk A/S
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Kyinsu is indicated for the treatment of adults with type 2 diabetes mellitus insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists as an adjunct to diet and exercise in addition to oral antidiabetic medicinal products. For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Novo Nordisk A/S |
|---|---|
| Active substance | Insulin icodec;semaglutide |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A10AE57 · Digestion, stomach, diabetes and nutrition |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2025-11-24 |
| Last updated by the regulator | 2026-02-12 |
| EMA product number | EMEA/H/C/006279 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).